Enhance Predictive In Vivo & In Vitro Oncology Models & Optimise Model Selection Balancing Translatability, Cost & Reproducibility to Better Predict Therapeutic Response

Welcome to the 13th Tumour Models London Summit!

With 5% of cancer drugs going into the clinic, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery, particularly with such a high price tag for clinical failure.

The 13th Tumour Models London Summit stands as the only industry-led meeting uniting pharma, biotech, and preclinical CROs from Europe to network and discuss new trends and innovations in tumour models. Attracting leading preclinical and translational expertise, this forum provides an essential platform for scientists and decision makers to hear about the latest innovations in in vivo and in vitro tumour modelling to de-risk their studies and accelerate their product’s journey from lab to patient.

Featuring in-depth industry discussions and actionable case studies, this event offers a unique exploration of the most pressing topics. Join the summit to:

Icon 1
Icon 2
Icon 3
Icon 4
Icon 5

Optimise Genomic Vendor Selection with AstraZeneca: Validate emerging genomic vendors by assessing the efficacy of various techniques to establish the most effective workflows and identify top service providers

Advance Precision Oncology with Econic Biosciences: Identify biomarkers of resistance and response in precision oncology using mono- and co-culture patient-derived organoids and xenopgraphs

Explore Human PDC Cell-Based Cancer Vaccines with PDC*line Pharma: Delve into the therapeutic potential of human PDC cell-based cancer vaccines by examining tumour resistance, evolution, and the tumour microenvironment in humanised mouse models

Unlock Novel Disease Insights with Digital Pathology & AI with Adaptimmune Therapeutics: Harness the power of digital pathology combined with AI analytics to gain groundbreaking insights into disease pathophysiology

Confidently Validate Drug Targets with 3D Models with AstraZeneca: Investigate the potential of 3D models to accurately validate drug targets and perform comprehensive preclinical safety assessments

 

Icon 1

Optimize Genomic Vendor Selection with AstraZeneca: Validate emerging genomic vendors by assessing the efficacy of various techniques to establish the most effective workflows and identify top service providers

Icon 2

Advance Precision Oncology with Econic Biosciences: Identify biomarkers of resistance and response in precision oncology using patient-derived organoids, comparing monoculture and co-culture models

Icon 3

Explore Human PDC Cell-Based Cancer Vaccines with PDC*line Pharma: Delve into the therapeutic potential of human PDC cell-based cancer vaccines by examining tumour resistance, evolution, and the tumour microenvironment in humanised mouse models

Icon 4

Unlock Novel Disease Insights with Digital Pathology & AI: Harness the power of digital pathology combined with AI analytics to gain groundbreaking insights into disease pathophysiology, presented by Adaptimmune Therapeutics

Icon 5

Confidently Validate Drug Targets with 3D Models with AstraZeneca: Investigate the potential of 3D models to accurately validate drug targets and perform comprehensive preclinical safety assessments

Expert Speakers Include

Philip Huxley

Philip Huxley
Vice President - Oncology

Bicycle Therapeutics

Madelon Paauwe

Madelon Paauwe
Senior Scientist Preclinical
In Vivo Pharmacology

Genmab

Paola Marco-Casanova

Paola Marco-Casanova
Director, Translational
Medicine, Oncology R&D

AstraZeneca

Wesley Minto

Wesley Minto
Senior Associate Scientist

Gilead Sciences

Mark Albertella

Mark Albertella
Senior Director – Oncology Biosciences

AstraZeneca

Nicholas Glanville

Nicholas Glanville
Vice President Research

Prokarium

Expert Speakers Include

Philip Huxley

Philip Huxley
Vice President - Oncology

Bicycle Therapeutics

Madelon Paauwe

Madelon Paauwe
Senior Scientist Preclinical
In Vivo Pharmacology

Genmab

Paola Marco-Casanova

Paola Marco-Casanova
Director, Translational
Medicine, Oncology R&D

AstraZeneca

Wesley Minto

Wesley Minto
Senior Associate Scientist

Gilead Sciences

Mark Albertella

Mark Albertella
Senior Director – Oncology Biosciences

AstraZeneca

Nicholas Glanville

Nicholas Glanville
Vice President Research

Prokarium

2024 Partners

xenostart
Certis Oncology
Gempharmatech
Genoway
Lide
Champions Oncology
Chempartner
Reaction Bio
Wuxi Apptec

" This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world "

Roche

Other Events in the Series